Intravitreal Bevacizumab versus Suprachoroidal Triamcinolone Acetonide for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Randomized Controlled Trial
European Journal of Clinical Pharmacy · 26.12.2025 · 7 (1) · 5284-5288
DOI: 10.61336/ejcp/25-12-600 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 26.12.2025.
Abstract (Originalsprache)
Background
Macular edema is the major cause of visual impairment in branch retinal vein occlusion (BRVO). Anti-vascular endothelial growth factor (anti-VEGF) agents are first line but corticosteroids are relevant where inflammatory permeability and treatment burden is an issue. Suprachoroidal delivery may have potential to increase the posterior segment exposure of the drug while potentially decreasing the anterior segment adverse effects.
Methods
This parallel group randomised controlled trial took place in LRBT Eye Hospital, Township Lahore, Pakistan (15 December 2023 to 14 June 2024). Adults aged 18-60 years with BRVO-associated macular edema were recruited using consecutive sampling and assigned (via a lottery method) in a 1:1 ratio to intravitreal bevacizumab (IVB) or suprachoroidal triamcinolone acetonide (STA). Baseline assessment consisted of best corrected vision (Snellen), slit lamp examination, dilated eye fundus examination, intraocular pressure and OCT-based central macular thickness (CMT). The primary endpoint was CMT change from baseline to 1 month.
Results
Sixty participants (30 each) participated in the 1 month follow up study. No significant difference was found between groups for baseline CMT (IVB 532.27+-9.08 um vs STA 530.00+-7.57 um; p=0.534). At 1 month, the mean CMT was 345.00+10.60 um in the IVB and 448.17+7.57 um in the STA group (p
Zitieren
APA
(2025). Intravitreal Bevacizumab versus Suprachoroidal Triamcinolone Acetonide for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Randomized Controlled Trial. European Journal of Clinical Pharmacy, 7(1), 5284-5288. https://doi.org/10.61336/ejcp/25-12-600
Vancouver
Intravitreal Bevacizumab versus Suprachoroidal Triamcinolone Acetonide for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Randomized Controlled Trial. European Journal of Clinical Pharmacy. 2025;7(1):5284-5288. doi:10.61336/ejcp/25-12-600
BibTeX
@article{euvimed2025,
title = {Intravitreal Bevacizumab versus Suprachoroidal Triamcinolone Acetonide for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Randomized Controlled Trial},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
number = {1},
pages = {5284--5288},
doi = {10.61336/ejcp/25-12-600}
}
EUVIMED